Barry Byrne, MD, PhD, Powell Gene Therapy Center at the University of Florida, discusses gene therapy considerations for pediatric patients and how newborn screening can influence outcomes for patients with Duchenne muscular dystrophy (DMD).
Barry Byrne, MD, PhD, pediatric cardiologist and director of the Powell Gene Therapy Center at the University of Florida, discusses considerations when administering gene therapies to pediatric patients and how newborn screening can influence outcomes for patients with Duchenne muscular dystrophy (DMD).
This transcript was lightly edited; captions were auto-generated.
Transcript
Are there unique considerations that must be taken into account when administering gene therapies to pediatric patients?
Our observations in clinical gene therapy as it relates to cardiopulmonary function confirm that in the setting of more advanced cardiomyopathy, like might be present in adults with Duchenne or in later-stage patients with conditions that affect both heart function and neurological function, like in Friedreich ataxia, we have to be mindful of the potential for inflammation in heart muscle cells that can be the result of the gene therapy treatment, and there are safety measures we follow to carefully monitor for those events in the first few weeks after gene therapy. Since the exposure to the heart muscle, like the rest of the musculature, is very high with AAV [adeno-associated virus]–mediated gene therapy, we also have to consider what might be the consequence of expression of a gene product that is not represented in the background of the given patient receiving the treatment, and there can be myocardial inflammation related to that. That's something we usually see after a month following the initial gene therapy. There's no difference in these events in pediatric or adult patients, so we take the same precautions and use the same continuous monitoring approach in all age groups.
DMD is not included in mandatory newborn screening in the US. Can you speak to how newborn screening can influence outcomes in DMD, particularly as gene therapies have become available?
The value of newborn screening as it relates to early detection of DMD, there's several aspects of it that have to be considered. One is that many patients are presymptomatic—or at least, the average age of detection from where there's sufficient separation from their peers is about 4 and a half years of age. When the mother is a carrier of a DMD mutation, if their older son is entering kindergarten or is [aged] 4 or 4 and a half, they may have had another child already, and so any males that are born subsequently to maternal carriers have the same increased risk of Duchenne as the initial sibling. [Therefore,] one consideration is this may help families in family planning.
Of course, there's also the notion that earlier treatment has potential for greater benefit, as is the case with most genetically defined diseases that are progressive or degenerative. Right now, we don't have any evidence that early treatment with the gene therapy product will be more effective, unless there's anticipation that the effect will be sustained over the lifespan, because as we grow, the muscle cells continue to divide and contribute to the ongoing repair of the muscle in Duchenne. And those repair cells, those ones that are responsible for regeneration of muscle, have not been corrected by the gene therapy vector, and therefore, over time, they would lessen the effect. And so there really is an urgent need in the case of early detection of Duchenne to consider how these patients will receive future treatment and sustain the effect over the lifespan.
The Push for Fair Pricing and Reform in Pharmacy Benefit Management
April 3rd 2025Amid growing legislative pressures and industry debates, pharmacy benefit managers (PBMs) are exploring new strategies to enhance transparency, reduce patient costs, and navigate the evolving healthcare landscape.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Using AI-Driven Strategies to Optimize Specialty Drug Costs, Manage Polypharmacy
April 2nd 2025As health care costs continue to rise, artificial intelligence (AI)-driven solutions are emerging as a powerful tool for managing specialty drug spending and polypharmacy risks, as showcased in recent research presented at the Academy of Managed Care Pharmacy 2025 conference.
Read More
How Recent Federal Policy Changes Are Shaping Managed Care Pharmacy
April 2nd 2025Federal legislative and regulatory changes are reshaping pharmacy practice, with key challenges in government funding, pharmacy benefit manager reform, and health care policy shifts—topics explored by experts at the Academy of Managed Care Pharmacy's annual meeting.
Read More
The IRA’s Unintended Consequences for Drug Pricing and Coverage
April 2nd 2025The Inflation Reduction Act (IRA) may be restricting Medicare Part D formularies, increasing patient costs, and stifling pharmaceutical innovation, experts warned at the Academy of Managed Care Pharmacy 2025 annual meeting.
Read More